We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other healthcare stocks.
The Evolving Landscape of Global Healthcare Spending and Innovation
The healthcare industry remains a vital and resilient sector which is driven by advancements in technology, increasing global demand, and an aging population. ReportLinker projects that the healthcare services industry will grow from $7.5 trillion in 2022 to $7.975 trillion in 2023. It is anticipated to increase at a compound annual growth rate (CAGR) of 6.3%, or $9.8 trillion, through 2027. The global healthcare market is divided into several segments, including hospitals, digital health, and healthcare services. The hospital market alone is predicted to grow by 4.18% a year between 2024 and 2029, reaching a market value of $5.19 trillion.
In 2021, worldwide healthcare spending reached a record $9.8 trillion, or 10.3% of global GDP, according to a report released by the World Health Organization in December 2023. Spending was not uniformly dispersed, either, with low-income nations becoming more dependent on foreign help as government health spending declined. High-income nations spent about $4,000 per capita on health care, but 11% of the world’s population resided in nations that spent less than $50 per person. Even while public health spending increased during COVID-19, this trend is unlikely to continue because nations are dealing with issues like high inflation, weak growth, and mounting debt.
According to the Centers for Medicare and Medicaid Services (CMS), national healthcare spending is projected to reach an estimated $4.8 trillion in 2023 and grow at an annual rate of 5.6% between 2027 and 2032.
A patient-centered, technology-driven revolution is taking place in the healthcare industry. Thanks to the epidemic, telehealth has become widely accepted; in 2023, the global market was estimated to be worth $60.15 billion and is predicted to continue growing. By 2028, the genomics-driven precision medicine market, which provides individualized therapies based on genetic composition, is expected to reach $50.2 billion. With $31.5 billion in equity funding from 2019 to 2022 and the potential for $360 billion in annual US savings over the next five years, AI is also revolutionizing healthcare. The global market for remote patient monitoring (RPM), which was valued at $71.9 billion in 2023, is expected to continue expanding thanks to wearable technology.
Dr Bruce Aylward, WHO Assistant Director-General, Universal Health Coverage, Life Course, said:
“Sustained public financing on health is urgently needed to progress towards universal health coverage. It is especially critical at this time when the world is confronted by the climate crisis, conflicts, and other complex emergencies. People’s health and well-being need to be protected by resilient health systems that can also withstand these shocks.”
The Looming Collapse of U.S. Healthcare
The most concerning aspect of the healthcare industry is the looming collapse of the U.S. healthcare system, particularly in terms of workforce shortages and financial instability. The healthcare industry is facing a severe staffing crisis. By 2030, it is projected that 124,000 more physicians will be needed, and 800,000 registered nurses (RNs) are anticipated to leave the profession by 2027. The current turnover rate for staff RNs is a staggering 24%. This shortage has led to the closure of vital patient services, including Pediatrics, Psychiatry, Obstetrics, and ICUs in some healthcare systems.
Despite these challenges, the U.S. continues to spend nearly twice as much on healthcare as the OECD average, with worse outcomes on average. This disparity highlights the inefficiency and unsustainability of the current system. Additionally, 58% of hospital bad debt comes from insured patients, further straining the revenue cycle and limiting funds available for clinical services. The combination of these factors paints a grim picture of the U.S. healthcare system’s future. Without significant intervention and reform, the industry risks a systemic collapse that could have far-reaching consequences for public health and the economy.
Our Methodology
In our methodology, we used a stock screener to pick stocks with a market capitalization above $10 billion and assessed their year-to-date (YTD) returns. We subsequently identified those with underwhelming YTD performance as of November 11 and ranked them accordingly.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma.
Genmab A/S (NASDAQ:GMAB)
Total YTD Return: -27.89%
Genmab A/S (NASDAQ:GMAB) is a Danish biotech company focused on developing antibody therapies for cancer and severe diseases, using advanced platforms like bispecific T-cell engagers, immune modulators, and antibody-drug conjugates.
Genmab A/S (NASDAQ:GMAB)’s TEPKINLY, the first subcutaneous bispecific antibody targeting cancerous B-cells, was approved by the European Commission and aims to revolutionize cancer treatment by 2030. In July, the FDA approved EPKINLY (epcoritamab-bysp) for adults with relapsed or refractory follicular lymphoma (FL) after two or more systemic therapies. The approval, based on an 82% overall response rate in clinical trials, makes EPKINLY the first subcutaneously administered T-cell engaging bispecific antibody for FL in the U.S. It’s also approved for diffuse large B-cell lymphoma.
Genmab A/S (NASDAQ:GMAB)’s stock hit a new 52-week low of $20.47, reflecting a significant drop from its previous highs, placing it among the worst performing healthcare stocks. The stock has shown a downward trend, with a 31.15% decrease over the past year which indicates ongoing challenges in maintaining investor confidence. In its latest earnings report, the company reported an earnings per share (EPS) of $0.29, which fell short of analysts’ expectations of $0.32. This miss contributed to negative perceptions about the company’s financial health and future growth prospects. It also reported revenue of $816.10 million, which was below the consensus estimate of $838.20 million. Such performance raises concerns about Genmab’s ability to generate sufficient revenue, especially in light of its ambitious goals in cancer treatment.
As tracked by the Insider Monkey database, 14 hedge fund holders held shares in Genmab A/S (NASDAQ:GMAB) in Q3 2024, with Renaissance Technologies being the largest stakeholder with shares worth $43.5 million.
Overall GMAB ranks 5th on our list of the worst performing healthcare stocks in 2024. While we acknowledge the potential of GMAB as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than GMAB but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
